OCUP – ocuphire pharma, inc. (US:NASDAQ)
Stock Stats
News
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $18.00 to $10.00. They now have a "buy" rating on the stock.
Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders
Ocuphire Pharma Announces Acquisition of Opus Genetics
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
Form 4 Opus Genetics, Inc. For: Oct 22 Filed by: Graves Adrienne L
Form 4 Opus Genetics, Inc. For: Oct 22 Filed by: Bennett Jean
Form 3 Opus Genetics, Inc. For: Oct 22 Filed by: YERXA BENJAMIN R
Form 3 Opus Genetics, Inc. For: Oct 22 Filed by: Graves Adrienne L
Form 3 Opus Genetics, Inc. For: Oct 22 Filed by: Bennett Jean
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.